Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

Pourcelot, Charlotte; Orillard, Émeline; Nallet, Gilles; Dirand, Camille; Billion-Rey, F.; Barbier, Garance; Chouk, Sarah; Limat, Samuel; Montcuquet, P.; Henriques, Julie; Paget‐Bailly, Sophie; Anota, Amélie; Chaigneau, L.; Nerich, Virginie

doi:10.1007/s10549-018-4676-3

Cited by 19 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients with HR+ (estrogen and/or progesterone) disease, the National Comprehensive Cancer Network (NCCN) recommends initiating hormonal therapy (HT) regardless of lymph node status, age, or whether chemotherapy is initiated . Given the established efficacy and favorable side effect profile, adjuvant HT is widely used to reduce disease relapse and breast cancer mortality, as well as improve disease‐free survival . Clinical trials have demonstrated that HT decreased the 5‐year and 10‐year breast recurrence rates while extending HT to 10 years further improves disease‐free survival …”

Section: Introductionmentioning

confidence: 99%

Delayed adjuvant hormonal therapy and its impact on mortality in women with breast cancer

et al. 2019

View full text Add to dashboard Cite

Adjuvant hormonal therapy (HT) is important for the management of hormone‐sensitive breast cancer. However, the timeliness for adjuvant HT and the consequences of delayed initiation of treatment have not been analyzed. The purpose of this study was to characterize delays to HT and assess the impact on clinical outcomes. The study cohort consisted of female patients with invasive ductal and/or lobular, hormone receptor‐positive breast cancer diagnosed between 2010 and 2015. Initiation of HT >6 months (180 days) after surgery was defined as delayed. Patients receiving chemotherapy were excluded from the study cohort. Multivariable logistic regression modeling was performed to establish associations between delayed HT and demographic, facility, and clinical factors. Survival analysis was performed using the Kaplan‐Meier estimation and Cox proportional hazards regression to evaluate overall survival. Of 179 590 women assessed in the National Cancer Database, 3.2% had a delay in the initiation of adjuvant HT. Positive demographic‐related risk factors were younger age, ethnic minority groups, and multiple comorbidities. Clinical factors significantly associated with delayed initiation of adjuvant HT were high‐grade tumor, larger tumor size, greater lymph node involvement, having an unplanned readmission within 30 days of surgery, and positive final surgical margins. Adjusted survival analysis showed a survival disadvantage of delayed initiation of HT. Risk factors for delayed initiation of HT specific to demographic and clinical characteristics were identified. Delayed initiation of HT was associated with a survival detriment.

show abstract

Section: Introductionmentioning

confidence: 99%

Delayed adjuvant hormonal therapy and its impact on mortality in women with breast cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Studies have reported high as well as low rates of adherence. 2,3,5 In our study, most participants reported that they had received information on the importance of ET, but interestingly, this information was mostly from their physicians rather than pharmacists. We found no association between the high adherence and the information provided by physicians which might be due to the nature of the study as there was no objective measure of the physician's role in patient's counseling.…”

mentioning

confidence: 63%

“…The questionnaire was developed by a survey specialist at our institution since, to our knowledge, there was no validated, well-established questionnaire in Arabic. The questionnaire contained items that were reported by Pourcelot et al 2 The questionnaire included questions on adherence (the number of missed doses of ET during the previous month) and type and duration of ET, perception about ET. The survey specialist and the clinical investigators assessed the items in term for clarity and relevance for the patients to establish the face and content validity of the questionnaire.…”

mentioning

confidence: 99%

Self-Reported Adherence to Oral Endocrine Therapy among Breast Cancer Patients in Jordan

Faqeer

Gharabli

Dalbah

et al. 2022

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

show abstract

“…Suggesting that 'patients should be educated' about the necessity of adhering to prescribed medication seems not to be very productive [40,49]. One might even make the case, consistent with the analyses in the WHO report on Adherence, that it is not the patient but rather the health care provider who should be educated about adherence as a complex aspect of human behavior.…”

Section: Discussionmentioning

confidence: 99%

Psychosocial determinants of adherence with oral anticancer treatment: ‘we don’t need no education’

et al. 2020

View full text Add to dashboard Cite

Introduction: Given the potentially fatal consequences of inadequate adherence with oral anticancer treatment in persons with cancer, understanding the determinants of adherence is vital. This paper aims at identifying psychosocial determinants of adherence to oral anticancer treatment. Methods: We reviewed the literature on psychosocial determinants of adherence with oral anticancer treatment, based on published literature in English, from 2015 to present. Literature searches were performed in PubMed, Embase, Web of Science, Cochrane library, Emcare, and PsychINFO, with 'cancer', 'medication adherence', 'psychology', and 'oral anticancer treatment' as search terms. The obtained 608 papers were screened by two independent reviewers. Results: In the 25 studies identified, illness perceptions, medication beliefs, health beliefs, and depression were found to be the major psychosocial determinants of adherence to oral anticancer treatment; sociodemographic and clinical characteristics were found to be of no major importance. The quality of the identified studies as assessed by two independent reviewers was found to be acceptable overall. The majority of papers were from North America and focused on patients with breast cancer; sample size varied from 13 to 1371; adherence was assessed with questionnaires derived from various theoretical models, pill counts and electronic pharmacy records; illness perceptions reflecting adaptive coping, and medication beliefs reflecting high necessity and low concerns were found to be associated with adherence. Conclusion: Psychosocial concepts are major determinants of adherence with oral anticancer treatment. 'Beliefs about medicines' and 'illness perceptions' in particular determine adherence with this treatment. Studies aiming at impacting adherence would benefit from interventions with a solid basis in behavioral theory in order to help health care providers explore and address illness perceptions and medication beliefs. Pre-consultation screening of adherence behavior may be a helpful supportive approach to improve adherence. Blaming the victim ('patients should be educated about the importance of adherence') is better replaced by encouraging health professionals to identify and address maladaptive psychosocial determinants of adherence.

show abstract

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

Cited by 19 publications

References 45 publications

Delayed adjuvant hormonal therapy and its impact on mortality in women with breast cancer

Delayed adjuvant hormonal therapy and its impact on mortality in women with breast cancer

Self-Reported Adherence to Oral Endocrine Therapy among Breast Cancer Patients in Jordan

Psychosocial determinants of adherence with oral anticancer treatment: ‘we don’t need no education’

Contact Info

Product

Resources

About